Cancer Genetics Inc. Announces Collaboration With Leading

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Cancer Genetics Inc. Announces Collaboration With Leading Oncology Researchers at Columbia University to Identify Genomic Signatures, Biomarkers and Novel Treatments for MDS and AML

> The collaboration will result in a novel, next-generation sequencing based panel for the improved diagnosis and prognosis of Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

> Nearly 100,000 people are living with MDS in the US, and both MDS and AML are increasing globally in incidence and prevalence.

> According to the National Cancer Institute, the five year survival rate of MDS is only 29 percent, and there is significant need for improved diagnosis and clinical management of the disease.

RUTHERFORD, N.J., Oct. 13, 2014 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX ) ("CGI" or "the Company"), an emerging leader in DNA-based diagnostics, announced today that it has entered into a research collaboration with Columbia University's Azra Raza, MD, director of the MDS Center and assistant professor of medicine at Columbia University Medical Center (CUMC), and Siddhartha Mukherjee, MD, PhD, assistant professor of medicine at CUMC, to identify more accurate diagnostic and prognostic markers for myelodysplastic syndromes (MDS), as well as novel therapies to target this class of bone marrow cancers. The ultimate goal of the collaboration is to develop personalized therapy for MDS patients and to enable accurate prediction of future treatment needs before patients become resistant to their current therapy or before their MDS progresses to the more aggressive acute myeloid leukemia (AML).

MDS represents a serious area of unmet need in cancer care. Approximately 15,000 new cases are diagnosed in the United States each year, and progression to AML occurs in about 30 percent of patients. Patients with MDS require frequent monitoring, and treatment for the disease can cost up to $50,000 per patient per year.

Through the development of a more detailed biologic characterization scheme for MDS, Cancer Genetics believes the collaboration will dramatically change the diagnosis, prognosis, and treatment of MDS. In addition to reconfirming the company's commitment to furthering personalized cancer treatment, the collaboration offers a potentially significant commercial opportunity for Cancer Genetics, as the company plans on developing unique next-generation sequencing (NGS) panels based on the work resulting from the collaboration

"We are very pleased to have the opportunity to collaborate with Dr. Raza and her world-class team at Columbia. The number of MDS cases diagnosed each year continues to increase as the population ages, and there is tremendous need for better outcome prediction and more individualized therapy options for these patients," said Panna Sharma, CEO of Cancer Genetics. "Working alongside Dr. Raza puts us at the forefront of revealing breakthroughs in MDS research and will allow us to address a class of diseases that can benefit enormously from personalized medicine."

"We are excited to be working with CGI on this collaboration," said Raza. "With more elaborate genomic sequencing, we will be able to make a significant leap in the quality of personalized care we can deliver to our MDS patients."

Raza, the collaboration's primary investigator, is a preeminent leader in MDS research. Through her clinical practice, she has established the largest single repository of MDS samples in the world, the MDS Tissue Repository. The repository contains approximately 50,000 samples from MDS patients, many of whom were followed for more than twenty years through disease progression and remission. Raza's contributions to the field of MDS are vast: In addition to her work as a clinician, she has made major scientific contributions to our understanding of the underlying biology of MDS. Significantly, she has been involved in the development and FDA approval of every drug on the market for MDS treatment, as well as dozens of Phase I–III studies on potential MDS-fighting agents.

For more information, please visit www.CancerGenetics.com , or follow Cancer Genetics on twitter @Cancer_Genetics .

About Cancer Genetics:

Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics , servicing some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals, as well as biopharma and biotech companies . Our state-of-the-art reference lab is focused entirely on maintaining clinical excellence and is both CLIA certified and CAP accredited and has licensure from several states including New York State. We have established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute. For further information, please see www.cancergenetics.com .

Forward Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Company's Form 10-Q for the quarter ended September 30, 2013 and other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.
 

Media Relations Paul Kuntz RedChip Companies, Inc. 800-733-2447, ext. 105 Investor Relations Michael Rice LifeSci Advisors, LLC 646-597-6997

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Scribd’s First Safety Report Shows Enforcement at Scale

Updated Category News Views 85

Forty-seven million enforcement actions is not a decorative statistic Scribd finally put some hard numbers on a problem most document platforms prefer to discuss in foggy corporate language. Its first transparency report, covering January through June 2026, says the company took more than 47 million moderation actions across Scribd and Slideshare. That is a hulking...

Continue Reading
SanMar’s Lott Tops Promo Products Power 50 Again in 2026

Updated Category News Views 65

Branded hoodies and logo tumblers rarely make Wall Street’s pulse race, but the numbers behind them deserve a hard look. Jeremy Lott, president and CEO of SanMar, was named the most influential leader in the U.S. promotional-products business for the second consecutive year, taking No. 1 in the 2026 Counselor Power 50 ranking. Awards can be fluff. A repeat win beside...

Continue Reading
A Decade of Giving: Light the World Initiative's Impact

Updated Category News Views 38

The Red Kiosk Revolution It's not every day that a church initiative pops up in global conversations, but here we are—ten years into the Light the World initiative by The Church of Jesus Christ of Latter-day Saints. What's interesting is how these little kiosks, like silent ambassadors, have become a staple in 145 spots this holiday season, spanning continents. Each...

Continue Reading
Iberostar's Grand Move: Opening in Zanzibar

Updated Category News Views 30

The Resort That Takes Your Breath Away Here we have Iberostar, boldly wading into the azure waters of the Indian Ocean, planting its flag on the sandy beaches of Zanzibar. This isn’t just another notch on the resort’s belt—it’s their first time setting up shop in East Africa, a move ripe with promise and adventure both. A Suite So Sweet 358 suites, mind you. Each...

Continue Reading
VeriSilicon's New AI/AR Glasses Tech: Game-Changer?

Updated Category News Views 34

VeriSilicon Unveils Next-Generation Subsystem There's some sizzle in the air with VeriSilicon's latest move in the wearable tech arena. They’ve launched a low-power, high-performance subsystem aimed squarely at AI and augmented reality glasses. Now, these gizmos aren't just the stuff of science fiction. Thanks to their Nano-XR series, reality might just get a splash...

Continue Reading
ISDN Holdings: Leading APAC Automation with Innovation

Updated Category News Views 68

Pioneering Automation Intelligence in APAC Not every day you hear a company quietly revolutionizing an entire industry's landscape—but ISDN Holdings Limited is one of those rare players. Recognized by Frost & Sullivan for its top-tier customer value leadership, ISDN is making waves across the Asia-Pacific's industrial scene with its integrated industrial automation...

Continue Reading
Triple Crossing Tests a Tough Inland Marine Market

Updated Category News Views 105

Inland marine is where tidy insurance appetites go to get bent out of shape. A contractor’s rented machine, cargo moving between points, a half-finished building, or equipment that is neither parked forever nor easy to classify can turn a standard quote into a week of broker phone calls. Triple Crossing Specialty is stepping directly into that mess, launching a new...

Continue Reading
Max y Noelia Explore Trade at 9th CIIE in Shanghai

Updated Category News Views 23

Influencers at the Heart of Global Trade Exploration Makin' their debut on the big stage of the 9th China International Import Expo (CIIE), Mexican influencers Max y Noelia found themselves caught in a whirlwind of trade and cultural exchanges over in Shanghai. These digital mavens aren't just snapping selfies. Nope, they're capturing the very essence of international...

Continue Reading
RBI Prices $1 Billion of Secured Notes Due 2031, 2036

Updated Category News Views 189

A billion dollars of fresh paper just landed on Restaurant Brands International’s balance-sheet doorstep, and this one deserves more than the usual sleepy glance at a financing release. RBI has priced $500 million of 6.00% senior secured notes due 2031 and another $500 million of 6.40% senior secured notes due 2036. The expected closing date is November 24, 2026,...

Continue Reading
Spruce Spins Adrenyx En Route to Nasdaq in 2027

Updated Category News Views 67

New Frontiers: Adrenyx Biosciences Takes Shape Well, here's a new chapter in biotech drama. Spruce Biosciences, a name you might have tangled with if you're into tickers like NASDAQ:SPRB, just carved out a niche with the birth of Adrenyx Biosciences. The play? A separate company eyeing the endocrinology space, setting its sights on tackling congenital adrenal hyperplasia...

Continue Reading

Top 5 Most Recently Viewed Articles

Butterfly Network and Rutgers Study Show Impact of POCUS

Updated Category News Views 129

Revolutionizing Hospital Care with POCUS Technology BURLINGTON, Mass. & NEW YORK-- Butterfly Network, Inc. (NYSE: BFLY), a pioneering digital health company, has launched a significant study in collaboration with Rutgers Robert Wood Johnson Medical School. This research emphasizes the transformative influence of point-of-care ultrasound (POCUS) technology on patient...

Continue Reading
Civista Bancshares Increases Quarterly Dividend to 17 Cents

Updated Category News Views 127

Civista Bancshares Boosts Quarterly Dividend Payments Civista Bancshares, Inc. (NASDAQ: CIVB), the financial cornerstone of Civista Bank, has made a noteworthy announcement regarding its quarterly dividends. The Board of Directors has approved a hike in the dividend to 17 cents per common share. This increment of 1 cent reflects the company's commitment to returning value...

Continue Reading
Argentinians Traveling Abroad for Cheaper Goods and Prices

Updated Category News Views 233

Argentinians Seeking Affordable Goods Abroad Amid rising domestic prices, it seems that many Argentinians are turning their eyes overseas in search of better deals on consumer goods. This trend has become evident as locals prioritize travel to countries like Brazil and Chile, where prices are significantly lower. The ongoing economic situation in Argentina, characterized...

Continue Reading
RomReal's Annual Report Insights and Audit Overview for 2024

Updated Category News Views 229

RomReal's Performance Overview for 2024 RomReal has been navigating a dynamic market landscape, with its annual report revealing insights into the company's financial health and operational resilience. The company has shown remarkable adaptability in the face of fluctuations within the industry, contributing to its performance in the 2024 fiscal year. This overview sheds...

Continue Reading
Microsoft's Flexible Work Policy: A New Era for Employees

Updated Category News Views 303

Microsoft rolled out a major statement back in 2024 that they're not gonna enforce a mandatory return-to-office unless they see productivity tank. Bigwigs at the company made it clear that for now, keeping things flexible is the name of the game. And why wouldn’t it be? With new hires flocking to companies that let them work from home, Microsoft knows they need to play...

Continue Reading